Apnea of prematurity: What's new?;Apnées du prématuré : données récentes

Archives de Pediatrie

Volumn 17, Issue 2, 2010, Pages 186-190

  Moriette, G ^a   Lescure, S ^a   El Ayoubi, M ^a   Lopez, E ^a  

^a université Paris Descartes ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE CITRATE; DOXAPRAM; XANTHINE DERIVATIVE;

ARTICLE; BRADYCARDIA; BRAIN OXYGEN CONSUMPTION; CEREBRAL PALSY; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; GESTATIONAL AGE; HEMODYNAMICS; HUMAN; HYPOXEMIA; IMMATURITY; INCIDENCE; LUNG DYSPLASIA; NEWBORN APNEA; OXYGEN SATURATION; PATENT DUCTUS ARTERIOSUS; POSITIVE END EXPIRATORY PRESSURE; PSYCHOPHYSIOLOGY; RESPIRATION CONTROL; TREATMENT INDICATION;

APNEA; BRADYCARDIA; BRAIN DAMAGE, CHRONIC; BRONCHOPULMONARY DYSPLASIA; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CITRATES; COMBINED MODALITY THERAPY; CONTINUOUS POSITIVE AIRWAY PRESSURE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; NEONATAL SCREENING; OXYGEN; RISK FACTORS;

EID: 74249109969     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2009.09.016     Document Type: Article

References (17)

1. Finer N.N., Higgins R., Kattwinkel J., et al. Summary proceedings from the apnea of prematurity group. Pediatrics 117 (2006) S47-S51
2. Idiong N., Lemke R., Lin Y.J., et al. Airway closure during mixed apneas in preterm infants: is respiratory effort necessary?. J Pediatr 133 (1998) 509-512
3. Abu-Shaweesh J.M., and Martin R.J. Neonatal apnea: what's new?. Pediat Pulmonol 43 (2008) 937-944
4. Martin R.J., Wilson G., Abu-Shaweesh J.M., et al. Role of inhibitory neurotransmitter interactions in the pathogenesis of neonatal apnea: implications for management. Semin Perinatol 28 (2004) 273-278
5. 2 inhalation for treating apnea of prematurity. J Pediatr 153 (2008) 513-518
6. Tourneux P., Cardot V., Museux N., et al. Influence of thermal drive on central apnea in the preterm neonate. Sleep 31 (2008) 549-556
7. Moriette G. Apnées. In: Laugier J., Rozé J.C., Siméoni U., and Saliba E. (Eds). Soins aux nouveau-nés (2006), Masson, Paris 255-258
8. Moriette G. Comment évaluer les conséquences cérébrales des apnées du prématuré ?. In: d'Ercole C. (Ed). Médecine périnatale (2004), Arnette, Rueil-Malmaison 267-274
9. Bass J., Corwin M., Gozal D., et al. The effect of chronic or intermittent hypoxia on cognition in childhood: a review of the evidence. Pediatrics 114 (2004) 805-816
10. Janvier A., Kharry M., Kokkotis A., et al. Apnea is associated with neurodevelopmental impairment in very low birth weight infants. J Perinatol 24 (2004) 763-768
11. Gaudelus J., Lefèvre-Ariche S., Roumegoux C., et al. Vaccination du prématuré. Arch Pediatr 14 (2007) S24-S30
12. Davis P.G., and Henderson-Smart D.J. Nasal continuous positive airway pressure immediately after extubation for preventing morbidity in preterm infants. Cochrane Database Syst Rev (2003) CD000143
13. Henderson-Smart D.J., and Steer P.A. Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst Rev (2001) CD000140
14. Schmidt B., Roberts R., Davis P., et al. Caffeine therapy for apnea of prematurity. N Engl J Med 354 (2006) 2112-2121
15. Schmidt B., Roberts R., Davis P., et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 357 (2007) 1893-1902
16. Henderson-Smart D.J., and Steer P.A. Doxapram versus methylxanthine for apnea in preterm infants. Cochrane Database Syst Rev (2000) CD000075
17. Sreenan C., Etches P.C., Demianczuk N., et al. Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea. J Pediatr 139 (2001) 832-837